Identification of Fully Human HCAbs Targeting CD19 for Cell Therapy using the NonaCarFxTM Platform
Time: 4:00 pm
day: Day One, Non Tracked PM
Details:
- Nona’s proprietary, clinically validated fully human heavy chain-only antibodies (HCAbs)
- Superior efficacy of HCAb-based CAR-T (NonaCARTM)
- Discovery of CD19-specific HCAbs using the NonaCarFxTM platform
